Overview

A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery

Status:
Terminated
Trial end date:
2018-11-08
Target enrollment:
0
Participant gender:
All
Summary
The investigators will track bariatric patients who received sugammadex versus neostigmine in the post anesthesia care unit until discharge and assess their length of stay and possible nausea / vomiting / hypoxia episodes.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Adam Thaler
Virtua Health, Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Neostigmine
Criteria
Inclusion Criteria:

- Patients having sleeve gastrectomy

- Surgeries performed by a particular surgeon - Dr. Sam Wasser

- Body Mass Index greater than 35

- American Society of Anesthesiologists Score II and III patients

Exclusion Criteria:

- Patients having a different type of bariatric surgery including but not limited to
duodenal switch, gastric bypass, hand-assisted laparoscopic sleeve gastrectomy

- Sleeve gastrectomy's performed by other surgeons than Dr. Sam Wasser.

- Pregnancy

- Allergic to sugammadex, Zofran or scopolamine

- Chronic Obstructive Pulmonary Disease or Asthma that is uncontrolled

- American Society of Anesthesiologists Score I, IV, V patients